Search alternatives:
significant challenges » significant challenge (Expand Search), significant changes (Expand Search)
challenges decrease » challenges case (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significant challenges » significant challenge (Expand Search), significant changes (Expand Search)
challenges decrease » challenges case (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
281
-
282
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
283
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
284
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
285
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
286
-
287
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
288
-
289
-
290
-
291
<i>Oenocarpus bacaba</i> palm tree (A) and fruit (B).
Published 2024“…Serological cure was achieved in 34.6% of cases, and IgG titers decreased in 15.3%.</p><p>Conclusions and significance</p><p>We encountered several barriers in managing ACD, including population vulnerability, reliance on outdated diagnostic techniques, lack of standardized molecular biology methods, and limited therapeutic options. …”
-
292
-
293
-
294
-
295
B2 decreases glycolytic intermediates in cells.
Published 2025“…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …”
-
296
-
297
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
Published 2025“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”
-
298
-
299
-
300
Predicted behavioural expression of young (orange) and old (blue) individuals that do (treatment) or do not (control) receive an immune challenge.
Published 2024“…<p>(a) If an immune challenge causes sickness behaviour then we expect that young and old immune-challenged individuals will decrease their population-level average behavioural expression compared with controls with old individuals decreasing their behavioural expression more than young individuals. …”